Enlibio,Your biological research partner
Xinqidi Biotech Co.,Ltd,Wuhan,China 2008-2022
R&D 14th year

Inactivation of the Hippo tumor suppressor pathway promotes melanoma

Issuing time:2022-07-01 14:51


Melanoma is commonly driven by activating mutations in the MAP kinase BRAF; however, oncogenic BRAF alone is insufficient to promote melanomagenesis. Instead, its expression induces a transient proliferative burst that ultimately ceases with the development of benign nevi comprised of growth-arrested melanocytes. The tumor suppressive mechanisms that restrain nevus melanocyte proliferation remain poorly understood. Here we utilize cell and murine models to demonstrate that oncogenic BRAF leads to activation of the Hippo tumor suppressor pathway, both in melanocytes in vitro and nevus melanocytes in vivo. Mechanistically, we show that oncogenic BRAF promotes both ERK-dependent alterations in the actin cytoskeleton and whole-genome doubling events, which independently reduce RhoA activity to promote Hippo activation. We also demonstrate that functional impairment of the Hippo pathway enables oncogenic BRAF-expressing melanocytes to bypass nevus formation and rapidly form melanomas. Our data reveal that the Hippo pathway enforces the stable arrest of nevus melanocytes and represents a critical barrier to melanoma development.


Cutaneous melanoma arises from the malignant transformation of melanocytes, which are neural crest-derived cells mainly localized to the basal layer of the epidermis. When locally resected, melanoma is highly curable; however, melanoma is the most aggressive of all skin cancers and distant-stage disease is associated with significant mortality1. Unraveling the molecular features underlying the pathogenesis of cutaneous melanoma is essential for the development of preventative and therapeutic treatment strategies.

The vast majority of melanocytic neoplasms are initiated by oncogenic mutations in the mitogen-activated protein kinase (MAPK) pathway, with activating mutations in BRAF and NRAS occurring in ~50% and ~20% of cutaneous melanomas, respectively2. Within BRAF-mutant melanomas, the most common activating mutation results from a single amino acid substitution from a valine to a glutamic acid generating the constitutively active mutant BRAFV600E3,4. Despite strongly inducing proliferative signaling, melanocyte-specific expression of BRAFV600E is insufficient to induce melanoma in multiple animal models; instead, BRAFV600E expression leads to the development of benign nevi (moles) comprised of growth-arrested melanocytes5,6,7,8,9,10. This is corroborated by clinical evidence as melanocytes within benign human nevi also frequently contain BRAFV600E mutations11,12 and these melanocytic nevi rarely transform into melanoma (annual rate <0.0005%)13. Similarly, mutations within NRAS are commonly detected in congenital nevi and oncogenic NRAS expression in melanocytes in vivo does not rapidly yield melanoma14,15,16. Although the risk of any single melanocytic nevus transforming into melanoma is minimal, understanding how such transformations occur is paramount as roughly one-third of all melanomas co-exist with or arise from nevi17.

These observations indicate that tumor suppression mechanisms restrain melanoma development following the acquisition of activating MAPK pathway mutations in melanocytes. A longstanding view is that strong oncogenic signals driven by mutations in MAPK pathway components lead to oncogene-induced cellular senescence (OIS), which safeguards against tumorigenesis18,19,20. Supporting this view, it has been demonstrated that expression of BRAFV600E in primary melanocytes in vitro induces an immediate cell cycle arrest and that these arrested melanocytes exhibit all of the hallmarks of oncogene-induced senescence: they become large, flat, vacuolar, express p16INK4A, display senescence-associated β-galactosidase (SA-β-gal) activity, and have increased heterochromatic foci and DNA damage18,21.

However, while it is clear that oncogene-induced senescence occurs in vitro, the extent to which this mechanism operates to ward off tumorigenesis in vivo remains unclear22,23,24. Several pieces of evidence argue against OIS as being the predominant mechanism restraining the proliferation of melanocytes harboring oncogenic mutations in vivo (extensively reviewed in ref. 16). Most notably, oncogene expression (e.g., BRAFV600E) in melanocytes does not induce an immediate proliferative block in vivo. Rather, these oncogenes initially induce proliferation, as evidenced by the clonal outgrowth of melanocytes that ultimately form a nevus, which requires many rounds of cell division. Furthermore, melanocytes lacking proteins known to enforce senescence, such as p16 and p53, retain the capacity to enter a growth-arrested state, as melanocytes in BrafV600E/Cdkn2a−/− and BrafV600E/Trp53−/− mouse models still primarily form nevi, with only a rare few melanocytes stochastically transforming into melanoma7.

Collectively, these data suggest that additional tumor suppressive mechanisms have the capacity to restrain the proliferation of BrafV600E-positive mouse melanocytes, independent of inducing senescence. Recent modeling studies have led to the postulation that the growth arrest of nevus melanocytes is not solely due to oncogene activation and OIS in individual cells, but rather due to cells sensing and responding to their collective overgrowth, similar to what occurs in normal tissues25. This cell growth arrest is reminiscent of the arrest induced by activation of the Hippo tumor suppressor pathway, which is an evolutionarily conserved pathway known to regulate organ size. When the Hippo pathway is activated, the Hippo kinases LATS1/2 phosphorylate the transcriptional co-activators YAP (YAP1) and TAZ (WWTR1), resulting in their inactivation by nuclear exclusion and subsequent degradation26,27. In contrast, when the Hippo pathway is inactivated, YAP and TAZ are active and form DNA-binding complexes with the TEAD family of transcription factors, which act synergistically with AP-1 complexes to stimulate the expression of genes mediating entry into the S-phase and cell proliferation28,29.

It is not known if Hippo pathway activation contributes to the growth arrest of nevus melanocytes. Moreover, while Hippo pathway inactivation has been suggested to promote cutaneous melanoma growth and invasion30,31,32, it remains unknown whether Hippo inactivation is sufficient to induce cutaneous melanoma initiation and/or progression. Here, we use a combination of in vitro and in vivo model systems to examine the role of the Hippo tumor-suppressor pathway in restraining melanoma development.


BRAF V600E expression activates the Hippo tumor-suppressor pathway in vitro

We sought to examine if the expression of BRAFV600E is sufficient to induce activation of the Hippo tumor-suppressor pathway in cultured melanocytes. Previous studies using primary melanocytes have demonstrated that exogenous expression of oncogenic BRAFV600E leads to an immediate p53-dependent growth arrest9,33. We, therefore, developed a system in which BRAFV600E expression could be induced without an immediate cell cycle arrest in an attempt to explore Hippo pathway activation over multiple cell cycles. To do so, we generated a doxycycline-inducible system to permit controlled BRAFV600E expression in non-transformed Simian Virus 40 (SV-40) immortalized melanocytes (Mel-ST cells)34. Expression of the SV-40 early region, which encodes the small and large T viral antigens, imparts immortality to primary melanocytes via multiple mechanisms including impairment of the p53/Rb pathways34. Induction of BRAFV600E expression in Mel-ST cells increased the phosphorylation levels of the downstream kinases ERK and RSK, indicating that the cell model successfully hyperactivates MAPK signaling upon the addition of doxycycline (dox) (Fig. 1a).

Fig. 1: BRAFV600E activates the Hippo tumor-suppressor pathway.
figure 1

a Representative immunoblot (IB) of dox-inducible BRAFV600E Mel-ST cells cultured ± dox for 24 h. b IB of two different dox-inducible BRAFV600E Mel-ST clones cultured ± dox for 24 h (n ≥ 4 independent experiments, graph shows mean relative intensity ± SEM, two-tailed unpaired t test). c Left, IB of two dox-inducible BRAFV600E Mel-ST clones cultured ± dox for 24 h; Right, intensity quantification of YAP phosphorylation from phos-tag gel (n = 4 independent experiments, graph shows mean relative intensity ± SEM, two-tailed unpaired t test). d Left, representative immunofluorescence staining of YAP/TAZ (green) alone or merged with DNA (DAPI, blue) and actin (Phalloidin, magenta) in indicated BRAFV600E Mel-ST clone; right, quantification of nuclear to cytoplasmic ratio of mean YAP/TAZ fluorescence (n > 300 cells from three independent experiments, graph shows mean ± SEM, scale bar = 20 µm, two-tailed Mann–Whitney test). e Relative expression of indicated genes from RT-PCR in BRAFV600E Mel-ST clones cultured ± dox for 24 h (n = 3 independent experiments, graph shows mean ± SEM, two-tailed unpaired t test). f Left, IB of primary human melanocytes infected with lentivirus that express control vector (H2B-GFP) or BRAFV600E; right, intensity quantification of YAP phos-tag (n = 3 independent experiments, graph shows mean ± SEM, two-tailed unpaired t test). Source Data are provided as a Source Data file.

To determine if BRAFV600E activates the Hippo tumor-suppressor pathway in vitro, we induced BRAFV600E expression and examined the relative levels of active, phosphorylated LATS1/2 at the hydrophobic motif (T1079)27. We found a significant increase in LATS phosphorylation following expression of oncogenic BRAFV600E (Fig. 1b). We then assessed total YAP phosphorylation (p-YAP) via phos-tag gel electrophoresis. We observed that BRAFV600E induction promoted phosphorylation of YAP at multiple sites (Fig. 1c). Consequently, expression of BRAFV600E led to nuclear exclusion of YAP and a corresponding decrease in the expression of the YAP target genes CYR61 and AMOTL2 (Fig. 1d, e and Supplementary Fig. S1A). The observed effects on LATS and YAP activity were due to BRAFV600E, as overexpression of wild-type BRAF had no effect on LATS or YAP phosphorylation (Supplementary Fig. S1B–E). We further confirmed these results in multiple cell lines, including non-immortalized primary adult human melanocytes with an intact p53 pathway (Fig. 1f and Supplementary Fig. S1F). Importantly, the observed effects of Hippo pathway activation were not limited to the expression of BRAFV600E alone, as we also found that inducible expression of oncogenic NRASQ61R similarly activates the Hippo pathway (Supplementary Fig. S1G). Collectively, these data demonstrate that hyperstimulation of the MAPK signaling pathway through the expression of oncogenic BRAFV600E or NRASQ61R leads to activation of the Hippo tumor-suppressor pathway in vitro.

Growth-arrested melanocytes in benign nevi show evidence of Hippo pathway activation

It is well established that melanocyte-specific expression of BrafV600E in animal models gives rise to benign nevi that harbor non-proliferating melanocytes5,25. We hypothesized that these BrafV600E-positive melanocytes may also demonstrate evidence of Hippo pathway activation, similar to our in vitro results. To test this possibility, we analyzed a single-cell RNA sequencing dataset of whole-skin extracts collected at postnatal days 30 (P30) and 50 (P50) from wild-type control mice and tamoxifen-painted Tyr::CreERT2/BrafCA mice expressing active BrafV600E25. We interrogated this dataset to examine if YAP/TAZ-dependent gene transcription was repressed in melanocytes expressing oncogenic BrafV600E. Following dimensionality reduction and initial clustering, we identified the cluster representing melanocytes based on the expression of the melanocyte-lineage marker Dct as previously reported (Fig. 2a)25. As expected, this cluster was found to have high expression of other melanocyte-lineage markers, notably Mlana and Mitf (Supplementary Fig. S2A). We then employed the variance-adjusted Mahalanobis (VAM) method, a scRNA-seq optimized approach to obtain accurate signaling pathway scores, to examine if YAP/TAZ-mediated gene expression was decreased in BrafV600E-expressing mouse melanocytes relative to wild-type melanocytes utilizing previously published YAP/TAZ gene expression profiles35,36,37. The most basic analysis, where all single cells were binned by genotype, demonstrated that YAP/TAZ gene expression targets were significantly reduced in BrafV600E-positive melanocytes compared to wild-type (Fig. 2b).

Fig. 2: BrafV600E-expressing nevus melanocytes display decreased YAP/TAZ signaling.
figure 2

a UMAP of relative Dct expression of all single cells from nevus containing murine skin identifying a cluster of cells representing melanocytes from GSE154679. b YAP/TAZ VAM scores for melanocytes from indicated genotypes (n = 46 for Braf+/+, n = 543 for BrafV600E/+, two-tailed Mann–Whitney test). c Top, UMAP of melanocytes colored by subcluster; Bottom, UMAP of melanocytes colored by genotype and animal age (n = 589). d YAP/TAZ VAM score plotted by melanocyte subcluster. e YAP/TAZ VAM score comparing nevus (clusters 0, 1) and other melanocytes (clusters 2, 3, 4) (nevus n = 408, other n = 181, two-tailed Mann–Whitney test). f UMAP of melanocytes colored by gradient indicating YAP/TAZ VAM score. g Representative immunofluorescence staining of indicated proteins in two benign nevi cases with two different sets of antibodies, (r) = rabbit, (m) = mouse, DAPI (blue), YAP (green), SOX10 (magenta), scale bar = 50 µm. Source Data are provided as a Source Data file.

We then performed unsupervised clustering, which generated five melanocyte subdivisions, to clarify which unique populations of oncogenic BrafV600E-expressing melanocytes exhibited the least YAP/TAZ activity (Fig. 2c). We theorized that clusters containing nevus melanocytes would be exclusively populated by cells isolated from BrafV600E mice, and be the primary melanocytic subtype isolated from 50-day-old mice. Based on these criteria, we identified clusters 0 and 1 as BrafV600E-expressing melanocytes isolated from nevi (Fig. 2c and Supplementary Fig. S2B, S2C). In support of this prediction, expression of Cdkn2a, which is upregulated in nevus melanocytes, was found to be the highest in clusters 0 and 1, although Cdkn2a read-depth was limited throughout all clusters (Supplementary Fig. S2D). Compared to all other melanocytes, nevus melanocytes (clusters 0 and 1) exhibited the lowest YAP/TAZ activity scores of any cluster, demonstrating that YAP/TAZ-mediated gene expression is reduced following oncogenic Braf expression in mouse nevus melanocytes (Fig. 2d–f). Importantly, expression of Hippo pathway components remained unchanged regardless of genotype or cluster, suggesting decreased YAP/TAZ signaling was due to Hippo pathway activation, not altered expression of YAP/TAZ regulators (Supplementary Fig. S2E, F).

Not all melanocytes captured from BrafV600E mice exhibited low YAP/TAZ activity scores. Clusters 2 and 4, which contain an appreciable portion of melanocytes from both Braf+/+ and BrafV600E mice, demonstrated much higher YAP/TAZ activity relative to nevus melanocytes (Supplementary Fig. S2G). However, within these clusters, YAP/TAZ activity was still decreased in BrafV600E melanocytes compared to wild-type cells. This suggests that cell-intrinsic mechanisms following BrafV600E expression are only partially leading to decreased YAP/TAZ activity and that other mechanisms, possibly cell-extrinsic cues, may play additional roles in vivo. We suspect cluster 3, the only cluster that did not exhibit this trend, may be comprised of proliferating, follicular melanocytes as this cluster mainly contains melanocytes isolated at P30 when most murine hair follicles are in anagen25. Taken together, these data reveal BrafV600E-expressing mouse melanocytes largely exhibit decreased YAP/TAZ activity, with the most significant decreases found within nevus melanocytes, strongly implying the Hippo pathway becomes activated in response to BrafV600E expression and nevus formation in vivo. In support of these conclusions, immunofluorescence staining of three human benign nevi revealed YAP localization to be predominantly cytoplasmic and thus presumably inactivated in human nevus melanocytes, consistent with a previous study using a validated YAP antibody (Fig. 2g)38.

BRAF V600E-induced Hippo activation restrains oncogenic melanocyte proliferation

We next investigated whether Hippo tumor-suppressor activation following BRAFV600E expression leads to reduced melanocyte proliferation in vitro. Population doubling assays demonstrated that expression of BRAFV600E reduced Mel-ST cell number ~30–40% relative to uninduced controls over a 4-day period, despite the fact these melanocytes were SV-40 immortalized (Fig. 3a). Live-cell imaging and proliferation assays revealed this was predominantly due to a proliferative arrest, rather than increased cell death (Supplementary Figs. S3A, B and 4A). To test whether the observed Hippo pathway activation induced by BRAFV600E expression was responsible for this proliferative defect, we used RNAi to knock down the LATS1/2 kinases in the context of BRAFV600E expression. We found that loss of LATS1/2 prevented YAP phosphorylation following induction of BRAFV600E and fully rescued cell growth and viability (Fig. 3b, c). We further found that inhibition of LATS1/2 with a potent small-molecule inhibitor also rescued cell growth (Fig. 3d)39. We then validated these findings using soft-agar growth assays. While parental Mel-ST cells and Mel-ST cells expressing BRAFV600E failed to efficiently grow under anchorage-independent conditions, Mel-ST cells expressing BRAFV600E together with a constitutively active YAP mutant (YAP-5SA) demonstrated significant colony formation (Fig. 3e and data not shown). These data reveal that functional inactivation of the Hippo pathway, through either LATS1/2 depletion/inhibition, or constitutive YAP activation, is sufficient to restore proliferation to BRAFV600E-expressing immortalized melanocytes in vitro.

Fig. 3: Oncogenic BRAF-induced Hippo pathway activation restrains melanocyte growth.
figure 3

a Population doubling assay of two dox-inducible BRAFV600E Mel-ST clones ± dox (n = 3 independent experiments, lines represent second-order polynomial non-linear fit, line color represents 95% confidence interval (dots show mean ± SEM, two-tailed unpaired t test). b Left, representative IB of two dox-inducible Mel-ST clones treated with control siRNA (siC) or LATS1 and LATS2 siRNAs (siLATS) ± dox for 24 h; right, intensity quantification of YAP phos-tag (n = 4 independent experiments, graph shows mean ± SEM, two-tailed unpaired t test). c Relative viability of Mel-ST cell lines treated with indicated siRNA or drugs for a 4-day period (n = 3 independent experiments in technical quintuplicate, graphs show mean ± SEM, two-tailed unpaired t test). d Number of population doublings of indicated dox-inducible Mel-ST clone over 4 days treated with either DMSO or a LATS1/2 inhibitor (LATSi), ± dox (n = 3 independent experiments, graph shows mean ± SEM, two-tailed unpaired t test). e Representative crystal violet stain of dox-inducible BRAFV600E Mel-ST cell line expressing indicated genes grown in dox-containing soft agar with quantification below (n = 2 independent experiments in technical triplicate, graph shows mean). f Plot of log2 copy-number values from TCGA-SKCM or GISTIC 2.0 calls from MSKCC-SKCM databases for the genes LATS1 and LATS2; bottom left percent is the frequency of LATS1/2 co-heterozygous loss. g Representative immunofluorescence staining of indicated proteins in three human melanoma cases, scale bar = 25 µm). Source Data are provided as a Source Data file.

We sought to determine to what extent human melanoma cells inactivate the Hippo pathway. We first interrogated the The Cancer Genome Atlas (TCGA), where we found that co-heterozygous loss of LATS1/2 is observed in ~15% of human melanomas (Fig. 3f and Supplementary Fig. S3C, D). We then stained a panel of human melanoma samples for YAP localization utilizing SOX10 as a marker for melanoma cells and, in agreement with previous studies, found that multiple melanoma tumors exhibited strong nuclear YAP localization, suggesting Hippo pathway inactivation (Fig. 3g and Supplementary Fig. S3E)31,38. Collectively, these data reveal that a subset of oncogenic melanocytes during melanomagenesis will overcome or bypass Hippo pathway activation to regain proliferative capacity.

BRAF V600E-induced Hippo activation is ERK-dependent and partially mediated by changes in the actin cytoskeleton

We sought to understand the mechanisms through which BRAFV600E directly or indirectly activates the Hippo tumor-suppressor pathway. Oncogenic MAPK signaling has previously been shown to impair mitosis, and complete mitotic failure can lead to the generation of tetraploid cells that activate the Hippo pathway40,41,42,43. We speculated that the expression of BRAFV600E may lead to Hippo pathway activation by disrupting the normal completion of mitosis. To test this possibility, we performed live-cell imaging of doxycycline-inducible BRAFV600E Mel-ST cells stably expressing the chromosome marker histone 2B-GFP (H2B-GFP). We observed that upon entering mitosis, cells expressing BRAFV600E often exhibited widely oscillating chromosomes and were unable to maintain a tightly aligned metaphase plate relative to uninduced controls (Fig. 4a). These chromosome alignment defects impaired the ability of many cells to satisfy the spindle assembly checkpoint, and consequently a portion of the BRAFV600E-expressing cells endured a significantly prolonged mitosis (Fig. 4a, b and Supplementary Fig. S4A, B). Cells that cannot satisfy the spindle assembly checkpoint either undergo mitotic cell death, or exit from mitosis without undergoing cell division, a phenomenon termed mitotic slippage44. Cells that undergo mitotic slippage often generate multinucleated tetraploid cells, and multinucleated melanocytes have been observed in human nevi42,44,45. We observed that upon induction of BRAFV600E the number of mitoses producing tetraploid cells increased significantly (control: 2.47%, induced: 24.75%) and was mainly driven by an increase in mitotic slippage (control: ~1%, induced: ~20%) (Fig. 4b and Supplementary Fig. S4B). These data demonstrate that BRAFV600E can impair mitosis leading to mitotic slippage and the formation of multinucleated tetraploid melanocytes in vitro. However, two lines of evidence suggested that mitotic errors leading to tetraploidization were not the major underlying driver of Hippo pathway activation in BRAFV600E-expressing melanocytes. First, BRAFV600E-expressing Mel-ST cells arrested in G1 (via thymidine) or G2 (via RO-3306-mediated CDK1 inhibition) still experienced Hippo activation despite their inability to become tetraploid (Supplementary Fig. S4C). Second, immunofluorescence experiments revealed that mononucleated diploid cells also exhibited decreased nuclear YAP/TAZ, demonstrating tetraploidization was not necessary to observe Hippo pathway activation (Fig. 1d).

Fig. 4: Prolonged MAPK activation leads to cytoskeletal defects and Hippo activation.
figure 4

a Representative fluorescence and phase-contrast images from a live-cell video of dox-inducible BRAFV600E Mel-ST cells expressing the chromosome marker H2B-GFP (green) cultured ± dox (scale bar = 25 µm, hh:mm). b Plot of mitotic duration and fate of individually tracked mitoses from (a) (n > 80 mitoses per condition from two independent experiments, graph shows mean ± SEM, dots represent individually tracked mitoses, black P value represent mitotic duration significance, two-tailed unpaired t test, blue P value represent significance for difference in frequency of whole-genome doubling events, two-sided Fisher’s exact test). c Left, IB of indicated dox-inducible BRAFV600E Mel-ST cell lines cultured ± dox for 24 h along with indicated drugs at the following doses: ERKi (20 nM), MEKi-1 (10 µM), MEKi-2 (20 nM); right, intensity quantification of YAP phos-tag (n = 3 independent experiments, graph shows mean ± SEM, one-way ANOVA with multiple comparisons). d Left, IB of dox-inducible BRAFV600E Mel-ST cell lines cultured ± dox for indicated time; right, intensity quantification of YAP phos-tag (n = 3 independent experiments, graph shows mean ± SEM, two-tailed unpaired t test). e Left, representative IB of dox-inducible BRAFV600E Mel-ST cell lines treated ± dox for 24 h or with 1 mM hydroxyurea for 6 h; right, intensity quantification of YAP phos-tag (n = 3 independent experiments, graph shows mean ± SEM, two-tailed unpaired t test). f Representative IB of RhoA-GTP pulldown in indicated dox-inducible BRAFV600E Mel-ST cell line ± dox; right, intensity quantification of RhoA-GTP to total RhoA (n = 3 independent experiments, graph shows mean ± SEM, two-tailed unpaired t test). Source Data are provided as a Source Data file.

We next investigated whether BRAFV600E specifically, or rather hyperactivation of the MAPK pathway generally, is responsible for Hippo pathway activation. We found that dampening of MAPK signaling via inhibition of the downstream kinases MEK1/2 or ERK1/2 fully prevented Hippo pathway activation, as measured by YAP/TAZ phosphorylation status, in BRAFV600E-inducible cell lines (Fig. 4c and Supplementary Fig. S5A). These data demonstrated that Hippo pathway activation is entirely mediated by general hyperactivation of MAPK signaling and requires factors downstream of ERK. These data also discounted the possibility that oncogenic BRAFV600E activates Hippo signaling via direct phosphorylation of key Hippo pathway components.

We noted that phosphorylation of YAP following BRAFV600E expression required sustained MAPK stimulation over a period of at least 12–16 h, as transient MAPK activation only minimally affected YAP phosphorylation (Fig. 4d and Supplementary Fig. S5B). We speculated that mounting oncogene-induced replication stress may be promoting Hippo pathway activation; however, induction of replication stress by hydroxyurea treatment alone was not sufficient to activate the Hippo pathway (Fig. 4e). Alternatively, it has been demonstrated that oncogenic activation of the MAPK pathway dramatically alters actomyosin cytoskeletal contractility and reduces RhoA activity in an ERK1/2-dependent manner46,47,48. Reductions in active RhoA are well known to promote Hippo pathway activation and, furthermore, ERK1/2-dependent cytoskeletal changes have previously been shown to modulate YAP/TAZ activity in melanoma cell lines40,49,50. We, therefore, posited that the reduction of RhoA activity may represent a mechanism by which BRAFV600E-expressing cells activate the Hippo pathway in vitro. Indeed, we observed that there was a significant reduction in the number of actin stress fibers in cells following activation of BRAFV600E, indicating reduced RhoA activity (Supplementary Fig. S5C, D). We then directly measured RhoA activity via pull-down assay, which revealed significantly decreased levels of active RhoA in Mel-ST cells expressing BRAFV600E relative to controls (Fig. 4f). These data suggest that BRAFV600E-induced Hippo pathway activation is at least partially mediated by prolonged MAPK hyperstimulation leading to ERK1/2-dependent cytoskeletal dysregulation. Supporting this view, endogenous BrafV600E expression in mouse embryonic fibroblasts has been shown to drastically reduce actin stress fibers, and a recent study has also demonstrated that expression of BRAFV600E in RPE-1 cells leads to decreased RhoA activity in vitro and cytokinesis failure in zebrafish (Darp et al. unpublished)51.

Lats1/2 −/− deletion promotes melanomagenesis

Our data suggested that functional inactivation of the Hippo tumor-suppressor pathway may enable BRAFV600E-expressing melanocytes to evade growth arrest and facilitate melanoma development. To test this, we generated mice carrying floxed alleles of both Lats1 and Lats252 with Tyr::CreERT2 to allow for inducible, melanocyte-specific inactivation of the Hippo pathway (Tyr::CreERT2/Lats1f/f/Lats2f/f). Deletion of LATS1/2 is well established to completely abrogate the Hippo pathway, and co-heterozygous loss of LATS1/2 is observed in ~15% of human melanomas, making deletion of Lats1/2 clinically relevant (Fig. 3f and Supplementary Fig. S3C, D)2,53. We also crossed Tyr::CreERT2/Lats1f/f/Lats2f/f (Lats1/2−/−) mice with mice expressing the Cre-activatable oncogenic Braf allele (BrafCA/+), generating Tyr::CreERT2/BrafCA/Lats1f/f/Lats2f/f (BrafV600E/Lats1/2−/−) mice (Fig. 5a and Supplementary Fig. S6A). We confirmed the melanocytic specificity of our Tyr::CreERT2 expressing mice via incorporation of a fluorescent lineage trace (YFPLSL), whose expression was only observed in cells that co-stained for melanocyte markers (Supplementary Fig. S6B).

Fig. 5: Lats1/2 deletion promotes melanoma formation.
figure 5

a Cartoon depicting 4-HT painting experiment. b Representative image of induced BrafV600E/Lats1/2−/− mouse tumor, scale bar = 0.5 cm. c Representative hematoxylin and eosin staining of spontaneous or induced tumors from BrafV600E/Lats1/2−/− mice, scale bar = 50 µm (n > 3 spontaneous tumors, n = 2 induced tumors from BrafV600E/Lats1/2−/− mice). d Representative IHC of indicated proteins, scale bar = 40 µm (n > 3 spontaneous tumors, n = 2 induced tumors from BrafV600E/Lats1/2−/− mice). e Representative image of induced Lats1/2−/− mouse tumor, scale bar = 0.5 cm. f Representative hematoxylin and eosin staining of induced flank tumor from Lats1/2−/− mouse, scale bar = 50 µm (n > 6 independent mice with similar results). g Survival plot from painting to study endpoint of Lats1/2−/− mice with 4-HT painted on flanks (Cre negative n = 4, Lats1/2−/− n = 7, log-rank test). h Representative IHC of indicated proteins, scale bar = 40 µm (n ≥ 3 Lats1/2−/− mice). i Cartoon depicting depilation experiment in Lats1/2−/− mice. j Percent palpable tumorigenesis in Lats1/2−/− mice at indicated time points (n = 10 mice, two-tailed unpaired t test). k Diameter of largest tumor on each animal measured at indicated time points (n ≥ 3 tumors measured at each timepoint with error bars ± SEM, ten mice total, two-tailed unpaired t test). Source Data are provided as a Source Data file.

We observed that BrafV600E/Lats1/2−/− mice were highly prone to developing spontaneous dermal tumors within weeks after birth, even without topical 4-hydroxytamoxifen (4-HT) administration. A similar melanoma mouse model, Tyr::CreERT2/BrafCA/Ptenf/f (BrafV600E/Pten−/−), has also been shown to be prone to spontaneous melanoma formation in the absence of topical 4-HT, due to leakiness of the inducible Cre recombinase54,55. This suggests that deletion of Lats1/2 plays a major role in promoting melanoma development, as BrafV600E expression alone in murine melanocytes does not generate tumors5,25 (Supplementary Fig. S6A). In the few mice where spontaneous tumorigenesis was absent or delayed, 4-HT administration to BrafV600E/Lats1/2−/− flanks resulted in the potent form of tumors which appeared histologically similar to the spontaneously arising neoplasms (Fig. 5b, c and Supplementary Fig. S6C). These tumors exhibited strong nuclear YAP/TAZ staining, indicating Hippo inactivation, and positively stained for the melanocytic markers SOX10 and S100 (Fig. 5d). SOX10 staining was nuclear and homogenous whereas S100 staining was weakly heterogeneous. Subsequent histopathologic analysis by a dermatopathologist confirmed these infiltrative, spindle cell tumors to be mouse melanoma. Unlike other BrafV600E-driven mouse melanoma models (e.g., BrafV600E/Cdkn2a−/−, BrafV600E/Trp53−/−), which still mainly induce nevus formation, we were unable to appreciate any obvious nevogenesis in BrafV600E/Lats1/2−/− mice. These data imply oncogenic BrafV600E-positive melanocytes may be incapable of entering an enduring growth arrest without a functional Hippo tumor-suppressor pathway.

We also investigated the consequences of Lats1/2 loss in melanocytes in the absence of oncogenic Braf. We found that following melanocyte-specific deletion of Lats1/2, mice exhibited no obvious hyperpigmentation, yet still rapidly developed cutaneous tumors with 100% penetrance after 4–5 weeks (Fig. 5e–g and Supplementary Fig. S6C–E). Co-heterozygous deletion of Lats1/2 also promoted cutaneous tumorigenesis, albeit at prolonged time scales (Supplementary Fig. S6F). Analysis of Lats1/2−/− tumor sections revealed non-pigmented neoplasms which were remarkably similar to invasive BrafV600E/Lats1/2−/− mouse tumors, exhibited a comparable staining profile, and were subsequently diagnosed as mouse melanoma (Fig. 5h). Previous studies have identified TEAD and AP-1 transcription factors as major regulators of the melanoma invasive state, which is marked by dedifferentiation and loss of pigmentation signatures56,57. We hypothesized that YAP/TAZ-TEAD activation, driven by Lats1/2 deletion, may enable melanocytes to directly access this invasive gene program explaining our observed lack of pigmentation. In support of this hypothesis, both BrafV600E/Lats1/2−/− and Lats1/2−/− mouse melanomas exhibited markedly low staining for mature, differentiated melanocyte markers (Supplementary Fig. S6G).

Given Lats1/2−/− tumors did not exhibit overt signs of pigmentation, we sought to generate additional data to validate that these neoplasms were melanocytic in origin. It has recently been demonstrated that initiation of the hair follicle cycle, via depilation, strongly promotes melanocyte transformation in BrafV600E/Pten−/− mice58,59. We leveraged this unique characteristic of mouse melanomagenesis to test if Lats1/2−/− tumor formation was also promoted by depilation, suggesting a melanocytic origin. We induced loss of Lats1/2 on opposing mouse flanks and then depilated only one flank so as to compare the tumorigenic rate from depilated and non-depilated regions (Fig. 5i). We observed that skin regions depilated following 4-HT treatment demonstrated significantly faster tumorigenesis, with palpable tumors observed in 70% of depilated areas compared to 20% of non-depilated areas about one month following treatment (Fig. 5j). Not only did tumors appear faster in depilated areas, but these tumors also grew significantly larger (Fig. 5k). Collectively, our data demonstrate that melanocyte-specific loss of Lats1/2 alone, or in conjunction with oncogenic Braf expression, promotes mouse melanocyte transformation and the formation of mouse melanoma.

We then investigated whether Hippo pathway inactivation was also occurring in other mouse models of melanoma. We performed gene set enrichment analyses (GSEA) using gene expression data collected from benign and transformed melanocytes from BrafV600E/Cdkn2a−/− and BrafV600E/Cdkn2a−/−/Lkb1−/− mice7. GSEA revealed that YAP/TAZ gene sets were significantly enriched in murine melanoma cells as compared to both arrested nevus melanocytes and proliferating non-tumorigenic melanocytes (Fig. 6a and Supplementary Fig. S7A–D). These data reveal that the Hippo tumor-suppressor pathway becomes attenuated as these murine melanocytes transform into melanoma.

Fig. 6: YAP activation promotes melanomagenesis.
figure 6

a GSEA performed on GSE61750 comparing enrichment of YAP/TAZ signatures in melanoma to arrested melanocytes in indicated genotype (see Supplementary Fig. S7A, S7D). b Left, representative IB of Mel-ST parental cell line treated with control siRNA (siC) or LATS1 and LATS2 siRNAs (siLATS); right, quantification of PTEN and p-S6 proteins compared to loading control or total protein (n = 3 independent experiments, graphs show mean ± SEM, two-tailed unpaired t test). c Top, representative IB of Mel-ST parental cell line expressing indicated plasmids, EV: empty vector; bottom, quantification of PTEN compared to loading control (n = 2 independent experiments, graph shows mean). d IB comparing D4M.3 A cells and Lats1/2−/− tumor lysates where numbers represent replicates or different tumors, respectively (n = 3 independent experiments or mice). e Left, survival curve of zebrafish with indicated genotypes; right, representative images of zebrafish with indicated genotype (n = 14 independent EGFP fish, n = 10 independent YAP-5SA fish, log-rank test). f Graph shows relative viability decrease (%) in indicated cell lines treated with 10 µM MGH-CP1 for 4 days (n = 3 independent experiments in ≥technical quintuplicate, graph shows mean ± SEM, one-way ANOVA with Dunnett’s multiple comparisons test). g Schematic model in which we propose overproliferation of melanocytes following acquisition of oncogenic BRAFV600E leads to increases in local melanocyte density, which subsequently promotes Hippo pathway activation and contributes to growth arrest and nevus formation. Functional impairment of the Hippo pathway, leading to YAP/TAZ activation, enables melanocytes expressing BRAFV600E to evade stable growth arrest and promote the development of melanoma. Source Data are provided as a Source Data file.

Active YAP drives melanoma development

We aimed to further define how deletion of Lats1/2 promotes melanoma development in vivo. While it is well-described that Lats1/2 loss functionally inactivates the Hippo pathway and leads to the activation of YAP and TAZ, LATS1/2 can also impinge upon additional signaling pathways that promote tumor development. For example, recent research has revealed inactivation of the Hippo pathway can promote mTOR signaling via multiple routes including YAP-driven expression of a micro-RNA, miR-29, which targets PTEN mRNA for silencing60,61,62. However, we detected no observable changes in PTEN protein level following either RNAi-mediated knockdown of LATS1/2 or expression of constitutively active YAP (YAP-5SA) or TAZ (TAZ-4SA) in Mel-ST cells (Fig. 6b, c). We also could not appreciate any significant change in phosphorylated S6 levels following LATS1/2 silencing (Fig. 6b). Furthermore, examination of Lats1/2−/− tumors revealed PTEN remained strongly expressed in vivo (Fig. 6d). These data reveal that loss of Lats1/2 is not driving melanomagenesis by activating mTOR via miRNA-mediated depletion of PTEN. It has also been demonstrated that active LATS2 can bind and inhibit MDM2 leading to increased p53 protein levels63, raising the possibility that deletion of Lats1/2 leads to decreases in p53, which may facilitate BrafV600E-driven murine melanomagenesis64. Discounting this, we found that p53 still accumulates in Lats1/2−/− tumors (Fig. 6d). Previous studies have also demonstrated that Lats1/2 knockout can induce cytokinesis failure and whole-genome doubling (WGD) in MEFs. Since WGD is well known to facilitate tumorigenesis, and a significant fraction of human melanomas are WGD, we speculated that Lats1/2 loss may drive tumorigenesis in vivo through an initial WGD event. To test this possibility, we performed copy-number analysis using ultra-low pass whole-genome sequencing (ULP-WGS) to examine if genomic alterations, such as WGD events, were enriched in BrafV600E/Lats1/2−/− tumors relative to BrafV600E/Pten−/− tumors. However, sequencing revealed that all tumors from these models were diploid, excluding the possibility that Lats1/2 deletion was primarily inducing melanoma through a WGD intermediate (Supplementary Fig. S8A).

We then assessed whether YAP activation alone was sufficient to promote melanoma development. To do so, we generated a transgenic zebrafish model that expresses constitutively active YAP (YAP-5SA) in zebrafish melanocytes utilizing the miniCoopR system65. These Tg(mitfa:YAP-5SA) zebrafish rapidly developed pigmented fish melanoma (Fig. 6e), demonstrating that constitutively active YAP is sufficient to induce melanoma development in a zebrafish model.

As activation of YAP/TAZ signaling was observed to promote melanomagenesis, we investigated whether depletion of YAP/TAZ could inhibit melanoma cell growth. RNAi-mediated knockdown of YAP/TAZ in the BrafV600E/Pten−/− mouse melanoma cell line (D4M.3A) resulted in significantly decreased viability as compared to immortalized melanocytes (Supplementary Fig. S7E). We further explored YAP/TAZ dependency in a panel of human melanoma cell lines utilizing the pan-TEAD inhibitor MGH-CP1 and found that a number of melanoma cell lines were strikingly sensitive to inhibition of YAP/TAZ activity (Fig. 6f and Supplementary Fig. S7F)66. While YAP1 is not commonly mutated in human melanoma, YAP1 amplifications and mutations have been observed, and YAP staining in primary melanoma has been shown to significantly correlate with reduced patient survival31,38,67. Together, these data implicate YAP as a cutaneous melanoma oncogene and novel therapeutic target to further explore in the treatment of human melanoma.


Discerning the molecular pathways that govern the growth arrest of nevus melanocytes, and how melanocytes ultimately overcome these barriers, is critical to fully understanding the mechanisms of melanomagenesis. A considerable body of work supports a role for OIS in preventing tumorigenic growth of melanocytes in vitro and in vivo; however, expanding lines of evidence demonstrate melanocytes within nevi retain proliferative capacity, in conflict with the absolute growth arrest implied by OIS16. Indeed, up to 30% of melanomas are predicted to arise from pre-cursor nevi17. These observations highlight nevi as being the product of “stable clonal expansion” rather than senescence16. Several genetic alterations that have the capacity to overcome the stable growth arrest of melanocytes expressing oncogenic MAPK mutations have been identified, including CDKN2A, PTEN, and TP533,5,6,7,64. While deletion of Cdkn2a and Trp53 with BrafV600E expression induces murine melanomagenesis, the vast majority of melanocytes still enter a stable growth arrest to form nevi7. Further, recent murine single-cell sequencing analyses reveal BrafV600E-positive nevus melanocytes do not exhibit expression of senescence signatures25. Together, these discoveries suggest additional unidentified tumor suppressive mechanisms exist to enforce the arrest of nevus melanocytes.

We discovered that expression of BRAFV600E promotes activation of the Hippo tumor-suppressor pathway across multiple cell lines and that BrafV600E-positive murine nevus melanocytes display significantly decreased YAP/TAZ signaling in vivo. Our data demonstrate that oncogenic BRAF expression induces Hippo pathway activation and cell cycle arrest in vitro by way of a cell-intrinsic mechanism, in which hyperactive MAPK signaling alters the cytoskeleton in part through decreased RhoA signaling and thus indirectly leads to Hippo pathway activation. However, our data also suggest that cell-extrinsic cues, perhaps secondary to the nevus microenvironment, may also be impinging upon YAP/TAZ signaling in vivo. Our single-cell sequencing analysis of mouse melanocytes indicated that while BrafV600E-expression leads to a general repression of YAP/TAZ signaling in most melanocytes, the effect is strongest in nevus melanocytes (Fig. 2d). A recent modeling study has proposed that the growth arrest of nevus melanocytes may be due to cells sensing and responding to their collective overgrowth, rather than cell-autonomous mechanisms25. This growth arrest model is highly analogous to the collective cell processes mediating contact inhibition and organ growth, which are governed by the Hippo pathway. It is therefore tempting to speculate that melanocyte overgrowth induced by oncogene expression significantly increases melanocyte density over multiple rounds of division, ultimately promoting mounting activation of the Hippo tumor-suppressor pathway, eventual growth arrest, and nevus formation (Fig. 6g). If true, one would predict Hippo pathway activation would only engage after a nevus passes a critical size threshold and that nevus melanocyte growth should be restored by reducing local melanocyte density. Intriguingly, nevi that are partially resected have been observed to regain proliferative capacity and the majority of these recurrent nevi did not grow beyond the limits of the original surgical scar, suggesting these nevus melanocytes arrest once they attain a similar size68,69. While growth arrest of oncogene-expressing melanocytes is conspicuous due the formation of pigmented nevi, it is also possible that oncogene-induced growth arrest of cells from other tissues is similarly mediated by activation of the Hippo pathway.

We also demonstrated that functional impairment of the Hippo pathway in melanocytes in vivo, either through deletion of Lats1/2 in mice or expression of constitutively active YAP1 in zebrafish, promotes cutaneous melanomagenesis. This finding has clinical relevance as co-heterozygous loss of LATS1/2 and amplification of YAP1 are observed in primary and metastatic human melanoma31,32,38. However, it should be noted that functional impairment of the Hippo pathway alone is not observed in human melanoma, and thus our model only partially replicates features of human tumors. Moving forward, it will be important to define additional mechanisms by which human melanoma cells circumvent the Hippo pathway to activate YAP38,70,71. For example, >80% of uveal melanomas and ~6% of cutaneous melanomas have mutations in GNAQ/GNA1 proteins, which stimulate RhoA activity and activate YAP/TAZ independent of any alterations in LATS1/272,73,74.

Our live-cell imaging also revealed that induction of oncogenic BRAF promotes chromosome alignment defects, prolonged mitosis, and mitotic or cytokinetic failures that lead to whole-genome doubling (WGD). Cells that have experienced a WGD (WGD+ cells) are genomically unstable and tumorigenic, and their contribution to human cancer is significant75,76,77. Oncogenic BRAF may therefore facilitate tumorigenesis not only by activating MAPK signaling, but also by increasing the baseline level of oncogenic WGD+ cells. However, while ~30–40% of all human melanomas, and the vast majority of human metastatic melanomas, demonstrate evidence of WGD78, our mouse melanoma models failed to exhibit this genomic feature (Supplementary Fig. S8). This is likely because the mouse models are already potently tumorigenic without the need for the additional oncogenic effects imparted by a WGD; nevertheless, the lack of any appreciable WGD in murine melanomas illustrates that these models have limitations in recapitulating the human disease45,76,77,78.

It is believed that activating MAPK mutations are critical for human melanocyte transformation; however, we found that murine melanocytes lacking Lats1/2 rapidly developed into melanomas without the initial presence of any other genetic alterations that stimulate the MAPK pathway. Questions therefore remain as to how Hippo pathway inactivation alone can so strongly promote melanoma development in mice. We observed that melanomas generated from Lats1/2−/− mice exhibited strong p-ERK staining. This suggests that the Lats1/2−/− melanocytes likely evolved to hyperactivate the MAPK pathway during their transformation, either through the acquisition of additional genetic alterations or, potentially, by stimulating or emulating MAPK activity through YAP/TAZ-dependent transcriptomic changes73. Indeed, it has been observed that one common resistance mechanism to Vemurafenib, a BRAFV600E-specific inhibitor, is the amplification and/or activation of YAP49,70,79. This suggests that YAP activity can compensate for loss of BRAFV600E signaling. Given MAPK inhibitor resistance remains a significant component of treatment failure, our data suggests that co-targeting MAPK and YAP-TEAD signaling could simultaneously prevent resistance70 and decrease melanoma cell viability32,80.

In summary, we demonstrate that activation of the Hippo tumor-suppressor pathway promotes melanocyte growth arrest in response to the expression of oncogenic BRAFV600E. Functional impairment of the Hippo pathway potently induces melanocyte growth in vitro and tumor development in vivo in multiple model organisms of melanomagenesis. Collectively, our data implicate the Hippo pathway as an important melanoma tumor suppressor and highlight YAP/TAZ as promising therapeutic targets to investigate for the treatment of human melanoma.

Article classification: Biological abstract
Share to:
Add:Room A11-329, 1st Floor, No.1, SBI Venture Street, Optics Valley, East Lake
New Technology Development Zone, Wuhan, China.
Certificate NO.:U18Q28010569R0S